Clinical Trials Browser

Terminated × Glioblastoma × Imatinib Mesylate × Clear all

NCT00171938 2017-02-24

Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)

Phase 2 Terminated

Brain Neoplasms, Glioblastoma

NCT00290771 2011-05-16

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

Phase 2 Terminated

231 enrolled 12 charts

Glioblastoma, Glioma